Over 90 nutritionists have hit back at Ozempic maker Novo Nordisk's project to update the Nova classification for ...

It is midday in Nairobi's Central Business District. I stroll downtown to see how easy it is to buy Ozempic, a drug sold in the Kenyan market as semaglutide and approved for diabetes but that is ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Anthropic on Monday closed its latest funding round at a $61.5 billion post-money valuation, the company confirmed to CNBC.

Though the Healthy Skepticism ads don’t specifically call out compounded GLP-1s, Lilly said in a statement to MM+M that ...

Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

What the telehealth prescribers can’t do, the compounders are. A major drug compounder association, the Outsourcing Facilities Association, along with member North American Custom Laboratories, LLC, ...

Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...